MedTrace Logo

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT06164704 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2025-08-15

No results posted yet for this study

Summary

The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and to assess the safety and tolerability of verekitug (UPB-101) compared to placebo.

Conditions

Interventions

DRUG

Verekitug (UPB-101)

Verekitug (UPB-101) 0.5 mL of formulated solution (100 mg verekitug \[UPB-101\])

DRUG

Placebo

Verekitug (UPB-101) matching placebo

Sponsors & Collaborators

  • Upstream Bio Inc.

    lead INDUSTRY

Principal Investigators

  • Kiran Patel, MD · Upstream Bio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-18
Primary Completion
2025-07-07
Completion
2025-07-22
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Germany
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06164704 on ClinicalTrials.gov